Published in Hypertension on June 25, 2012
Renal Denervation in Chronic Kidney Disease - RDN-CKD Study (RDN-CKD) | NCT04264403
Early reduction of therapy-resistant hypertension in a patient after single-sided renal denervation approach. Clin Res Cardiol (2013) 2.13
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol (2013) 1.78
Obesity-associated hypertension: recent progress in deciphering the pathogenesis. Hypertension (2014) 1.06
Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension (2013) 1.04
Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis (2013) 1.02
Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol (2013) 1.00
The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol (2014) 0.96
CrossTalk opposing view: Which technique for controlling resistant hypertension? Renal nerve ablation. J Physiol (2014) 0.93
Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol (2013) 0.91
Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol (2015) 0.89
Arterial stiffening provides sufficient explanation for primary hypertension. PLoS Comput Biol (2014) 0.88
Early life stress sensitizes the renal and systemic sympathetic system in rats. Am J Physiol Renal Physiol (2013) 0.87
Autonomic dysfunction in essential hypertension: A systematic review. Ann Med Surg (Lond) (2013) 0.87
The effects of catheter-based radiofrequency renal denervation on renal function and renal artery structure in patients with resistant hypertension. J Clin Hypertens (Greenwich) (2014) 0.86
Renal denervation after Symplicity HTN-3: an update. Curr Hypertens Rep (2014) 0.83
A novel method of selective ablation of afferent renal nerves by periaxonal application of capsaicin. Am J Physiol Regul Integr Comp Physiol (2014) 0.82
Review of the state of renal nerve ablation for patients with severe and resistant hypertension. J Am Soc Hypertens (2013) 0.81
Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease. Clin Kidney J (2013) 0.80
The sympathetic nervous system in obesity hypertension. Curr Hypertens Rep (2013) 0.80
MR-guided high-focused ultrasound for renal sympathetic denervation-a feasibility study in pigs. J Ther Ultrasound (2014) 0.80
Device-based approaches for renal nerve ablation for hypertension and beyond. Front Physiol (2015) 0.78
Renal sympathetic denervation in resistant hypertension. World J Cardiol (2013) 0.78
Differential role of afferent and efferent renal nerves in the maintenance of early- and late-phase Dahl S hypertension. Am J Physiol Regul Integr Comp Physiol (2015) 0.78
Renal denervation for the management of resistant hypertension. Integr Blood Press Control (2015) 0.78
Renal Denervation: A Potential Novel Treatment for Type 2 Diabetes Mellitus? Medicine (Baltimore) (2015) 0.77
Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). J Hum Hypertens (2015) 0.77
The effect of renal denervation on kidney oxygenation as determined by BOLD MRI in patients with hypertension. Eur Radiol (2015) 0.76
Renal denervation: intractable hypertension and beyond. Cardiorenal Med (2014) 0.75
Treating resistant hypertension: role of renal denervation. Integr Blood Press Control (2013) 0.75
Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs. BMC Cardiovasc Disord (2017) 0.75
Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. Korean Circ J (2016) 0.75
Renal sympathetic denervation for resistant hypertension treatment : current perspectives. Arq Bras Cardiol (2013) 0.75
Role of the renal sympathetic nerves in renal sodium/potassium handling and renal damage in spontaneously hypertensive rats. Exp Ther Med (2016) 0.75
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide. Dis Markers (2015) 0.75
Diagnostic value of urinary protein and creatinine in combination with renal ultrasound examination in early renal damage of patients with hypertension. Pak J Med Sci (2015) 0.75
Effects of Renal Denervation on Renal Artery Function in Humans: Preliminary Study. PLoS One (2016) 0.75
Novel Approaches for the Treatment of the Patient with Resistant Hypertension: Renal Nerve Ablation. Curr Cardiovasc Risk Rep (2013) 0.75
Sympathetic renal denervation in hypertension with chronic kidney disease: a case report and review of literature. Int J Clin Exp Med (2015) 0.75
Percutaneous renal sympathetic denervation for the treatment of resistant hypertension with heart failure: first experience in Korea. J Korean Med Sci (2013) 0.75
Renal Artery Vasodilation May Be An Indicator of Successful Sympathetic Nerve Damage During Renal Denervation Procedure. Sci Rep (2016) 0.75
Bipolar radiofrequency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-year results from the REDUCE-HTN trial. J Hum Hypertens (2017) 0.75
Long-term quality of life and clinical outcomes in patients with resistant hypertension treated with renal denervation. Postepy Kardiol Interwencyjnej (2016) 0.75
Effects of renal denervation on vascular remodelling in patients with heart failure and preserved ejection fraction: A randomised control trial. JRSM Cardiovasc Dis (2017) 0.75
Beyond blood pressure: percutaneous renal denervation for the management of sympathetic hyperactivity and associated disease states. J Am Heart Assoc (2015) 0.75
Renal denervation and blood pressure reduction in resistant hypertension: a systematic review and meta-analysis. Open Heart (2014) 0.75
Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography. Eur Radiol (2017) 0.75
Renal denervation in the treatment of resistant arterial hypertension. Wien Med Wochenschr (2014) 0.75
Targeting neural reflex circuits in immunity to treat kidney disease. Nat Rev Nephrol (2017) 0.75
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 12.03
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet (2009) 10.53
Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol (1985) (2010) 9.76
Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med (2010) 4.42
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A (2005) 4.13
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol (2012) 3.56
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int (2011) 3.32
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med (2008) 3.21
Update on myocarditis. J Am Coll Cardiol (2012) 3.12
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60
Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation (2003) 2.59
Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res (2003) 2.56
Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol (2002) 2.54
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation (2002) 2.38
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med (2009) 2.28
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation (2005) 2.25
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res (2006) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med (2007) 2.20
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med (2009) 2.18
Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension (2012) 2.17
Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J (2010) 2.12
Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation (2009) 2.09
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension (2008) 2.09
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil (2011) 2.05
Predictors of outcome in patients with suspected myocarditis. Circulation (2008) 2.03
Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol (2003) 2.01
Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension (2010) 2.01
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2007) 1.99
Pulsatile venoarterial perfusion using a novel synchronized cardiac assist device augments coronary artery blood flow during ventricular fibrillation. Artif Organs (2014) 1.99
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96